<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531865</url>
  </required_header>
  <id_info>
    <org_study_id>FRSDRM</org_study_id>
    <nct_id>NCT04531865</nct_id>
  </id_info>
  <brief_title>Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment</brief_title>
  <official_title>Efficacy and Safety of Mycophenolate Mofetil as Maintenance Therapy After Rituximab Treatment in Childhood-onset, Frequently-relapsing or Steroid-dependent Nephrotic Syndrome: a Multicenter Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate&#xD;
      Mofetil following single course of Rituximab in maintaining remission over 12 months among&#xD;
      Children with frequently-relapsing or steroid-dependent nephrotic syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of multiple observational studies and randomized control trials have shown that&#xD;
      Rituximab, a chimeric monoclonal antibody against the cluster of differentiation antigen 20&#xD;
      (CD20) antigen on B cells, is safe and effective for children with complicated&#xD;
      steroid-dependent/ frequently-relapsing nephrotic syndrome (SDFRNS) without corticosteroid or&#xD;
      immunosuppressive therapy. Single rituximab infusion has been shown to be efficacious for 6&#xD;
      to 12 months, the reported median relapse-free period was 9 months. Our previous study found&#xD;
      that Mycophenolate mofetil can further improve the sustained remission time.&#xD;
&#xD;
      All patients will be treated with 2 doses of Rituximab 375 mg/m2 iv at time 0 and 7 days.&#xD;
      Addition of Maintenance Mycophenolate Mofetil or placebo from 4 Month onwards. The expected&#xD;
      duration of the follow-up is 12 months, consisting of 12 visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year relapse-free survival rate</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The rate of no relapse within 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The concentration for MPA-area under curve(AUC)</measure>
    <time_frame>At 48 weeks</time_frame>
    <description>Blood concentrations of mycophenolic acid (MPA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a relapse</measure>
    <time_frame>6 months period after randomization</time_frame>
    <description>The proportion of patients with relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse (days)</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>Number of days from randomization to occurrence of first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-Cell Recovery Time</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>Time to the first detection of CD19+ cells above 1% of total CD45+ lymphocytes after CD19+ cell depletion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth velocity</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The standard deviation scores (SDS) for height at 12th month minus that of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>It is a binary variable (1/0). The varibale would be setted as &quot;1&quot; if any adverse events occours including early infusion termination, acute infusion reaction Infection, pulmonary fibrosis, encephalopathy, neutropenia. Adverse events graded according to Common Terminology Criteria For Adverse Events (NCI-CTCAE v4.03)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Frequently Relapsing Nephrotic Syndrome</condition>
  <condition>Steroid-Dependent Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rituximab and Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab: 375 mg/m2 intravenously on day 0 and day 7</description>
    <arm_group_label>Rituximab Only</arm_group_label>
    <arm_group_label>Rituximab and Mycophenolate Mofetil</arm_group_label>
    <other_name>Rituximab Biosimilar HLX01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.</description>
    <arm_group_label>Rituximab and Mycophenolate Mofetil</arm_group_label>
    <other_name>Mycophenolate Mofetil Dispersible tablets（CYCOPIN®）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets matching Mycophenolate Mofetil</intervention_name>
    <description>Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.</description>
    <arm_group_label>Rituximab Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children between 1 and 16 years with Frequently-relapsing or Steroid-dependent&#xD;
             Nephrotic Syndrome&#xD;
&#xD;
          2. Estimated glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m2 at study entry.&#xD;
&#xD;
          3. Remission at study entry&#xD;
&#xD;
          4. Patients in whom ≥5 CD20-positive cells/μL are observed in the peripheral blood.&#xD;
&#xD;
          5. Parents willing to give informed written and audiovisual consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have been diagnosed with nephritic- NS, such as immunoglobulin A(IgA)&#xD;
             nephropathy, prior to assignment or in whom secondary NS is suspected.&#xD;
&#xD;
          2. Patients showing one of the following abnormal clinical laboratory values:&#xD;
&#xD;
        1) Leukocytes &lt; 3000/μL. 2) Neutrophils &lt; 1500/μL. 3) Platelets &lt; 50,000/μL. 4) Alanine&#xD;
        aminotransferase (ALT) &gt; 2.5× upper limit of normal value. 5) Aspartate aminotransferase&#xD;
        (AST) &gt; 2.5× upper limit of normal value. 6) Positive for hepatitis B surface (HBs)&#xD;
        antigen, HBs antibody, hepatitis B core (HBc) antibody, or hepatitis C virus (HCV)&#xD;
        antibody. 7) Positive for HIV antibody.&#xD;
&#xD;
        3. Patients meeting one of the following infection criteria:&#xD;
&#xD;
        1) Presence or history of severe infections within 6 months prior to assignment.2) Presence&#xD;
        or history of opportunistic infections within 6 months prior to assignment.3) Presence of&#xD;
        active tuberculosis.4) Patients with a history of tuberculosis or in whom tuberculosis is&#xD;
        suspected.5) Presence or history of active hepatitis B or hepatitis C or hepatitis B virus&#xD;
        carrier.6) Presence of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
        4. Presence or history of angina pectoris, cardiac failure, myocardial infarction, or&#xD;
        serious arrhythmia (findings observed under Grade 4 of the Common Terminology Criteria for&#xD;
        Adverse Events (CTCAE)).&#xD;
&#xD;
        5. Presence or history of autoimmune diseases or vascular purpura.&#xD;
&#xD;
        6. Presence or history of malignant tumor.&#xD;
&#xD;
        7. History of organ transplantation.&#xD;
&#xD;
        8. History of drug allergies to methylprednisolone, acetaminophen, cetirizine,&#xD;
        mycophenolate mofetil,rituximab, or any of the above drugs&#xD;
&#xD;
        9. Uncontrollable hypertension.&#xD;
&#xD;
        10. Having received a live vaccine within 4 weeks prior to enrollment.&#xD;
&#xD;
        11. Patients who do not agree with contraception during the study period.&#xD;
&#xD;
        12. Judged inappropriate for this study by the treating or study physicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu Hong, PhD.MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's hospital of Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

